Autopsy report · NCT00955240

Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer

“Inadequate toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 1 year 8 months before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

UNICANCER

Sponsor type

University, hospital or other

Conditions

Anal Cancer

Interventions

cetuximab; cisplatin; fluorouracil; laboratory biomarker analysis; radiation therapy

Participants

16

Sites

20

Countries

France

Trials that died the same way

• A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
  “Toxicity” (88% match in meaning)
• A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
  “Extreme toxicity” (84% match in meaning)
• In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
  “Dose Limiting Toxicities” (66% match in meaning)
• GFM-Acadesine: A Phase I-II Trial of Acadesine
  “Renal toxicity” (64% match in meaning)
• Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
  “Number of known toxicities observed despite a treatment-naïve population” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.